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Background: Tuberculosis (TB) in young and HIV-infected children is frequently diagnosed at hospital level. In
settings where general hospitals do not function as TB reporting units, the burden and severity of childhood TB
may not be accurately reflected in routine TB surveillance data. Given the paucibacillary nature of childhood TB,
microbiological surveillance alone will miss the majority of hospital-managed children. The study objective was to
combine complementary hospital-based surveillance strategies to accurately report the burden, spectrum and
outcomes of childhood TB managed at referral hospital-level in a high TB burden setting.
Methods: We conducted a prospective cohort study including all children (< 13 years) managed for TB at a large
referral hospital in Cape Town, South Africa during 2012. Children were identified through newly implemented
clinical surveillance in addition to existing laboratory surveillance. Data were collected from clinical patient records,
the National Health Laboratory Service database, and provincial electronic TB registers. Descriptive statistics were
used to report overall TB disease burden, spectrum, care pathways and treatment outcomes. Univariate analysis
compared characteristics between children identified through the two hospital-based surveillance strategies to
characterise the group of children missed by existing laboratory surveillance.
Results: During 2012, 395 children (180 [45.6%] < 2 years) were managed for TB. Clinical surveillance identified 237
(60%) children in addition to laboratory surveillance. Ninety (24.3%) children were HIV co-infected; 113 (29.5%) had
weight-for-age z-scores <− 3. Extra-pulmonary TB (EPTB) was diagnosed in 188 (47.6%); 77 (19.5%) with
disseminated TB. Favourable TB treatment outcomes were reported in 300/344 (87.2%) children with drug-
susceptible and 50/51 (98.0%) children with drug-resistant TB. Older children (OR 1.7; 95% CI 1.0–2.8), children with
EPTB (OR 2.3; 95% CI 1.5–3.6) and in-hospital deaths (OR 5.4; 95% CI 1.1–26.9) were more frequently detected by
laboratory surveillance. TB/HIV co-infected children were less likely to be identified through laboratory surveillance
(OR 0.3; 95% CI 0.2–0.5).
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Conclusions: The burden and spectrum of childhood TB disease managed at referral hospital level in high burden
settings is substantial. Hospital-based surveillance in addition to routine TB surveillance is essential to provide a
complete picture of the burden, spectrum and impact of childhood TB in settings where hospitals are not TB
reporting units.
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In 2016, South Africa remained the country with the
highest estimated total tuberculosis (TB) incidence globally
(781 per 100,000 population) with an estimated total of
438,000 TB cases, 58,000 occurring in children < 15 years
[1]. The South African National TB Programme (NTP) has
a decentralized model of TB care, supporting adult and
paediatric patients to primarily receive diagnostic and treat-
ment services at community-based primary healthcare
(PHC) facilities [2]. Routine TB recording and reporting
tools, including TB treatment registers, are therefore typic-
ally located at community-based PHC facilities. Data from
the TB registers are captured and aggregated into two elec-
tronic registers used routinely for reporting NTP TB sur-
veillance data: ETR.Net (drug-susceptible TB [DS-TB]), and
EDRWeb (drug-resistant TB [DR-TB]). In the Western
Cape Province, general hospitals do not function as TB
reporting units therefore inclusion of adults and children in
routine TB surveillance data rely on patients accessing
treatment at PHC facilities.
In the absence of TB preventive therapy, young children
(< 5 years of age) have a high risk of progressing to TB dis-
ease and to severe forms of TB once infected with Myco-
bacterium tuberculosis (M. tb) [3]. Young children are also
frequently diagnosed with TB at the referral healthcare
level (secondary or tertiary hospital) due to diagnostic
challenges, including the ability to obtain adequate sam-
ples for TB microbiological testing. Children may fre-
quently move between community and hospital-based
healthcare services during the course of TB diagnosis and
treatment [4]. A previous audit at a large referral hospital
in this setting, Tygerberg Hospital (TBH) found that only
62% of children with culture-confirmed TB were included
in routine TB surveillance data during 2007–2009, and
that children with TB meningitis and children who died in
hospital were more likely not to be included in NTP sur-
veillance data [5]. In settings where hospitals do not func-
tion as TB reporting units, hospital-based surveillance data
is critical to supplement NTP surveillance data in order to
have an accurate reflection of the burden and spectrum of
TB in children.
Hospital-based laboratory surveillance of childhood
TB has provided valuable insight into the epidemiology
and trends in drug resistance in the Western Cape Prov-
ince since 2003 [6–10]. However, given the paucibacillarynature of TB in children with only 25–40% of children
treated for TB expected to have bacteriologically con-
firmed disease [11–13], laboratory surveillance in isolation
will miss the majority of children with TB managed at
hospital-level. Hospital-based clinical surveillance strat-
egies are therefore needed to identify children with an un-
confirmed, clinical TB diagnosis.
In order to document the true burden and spectrum
of childhood TB managed at a large referral hospital in a
TB endemic setting we conducted a prospective one-
year, hospital-based surveillance study at TBH, Cape
Town. We implemented new clinical surveillance activ-
ities in addition to existing laboratory surveillance to
identify all children routinely diagnosed with or treated
for TB. We compared TB disease spectrum, clinical
characteristics, care pathways and treatment outcomes
between children identified through the two comple-
mentary hospital-based surveillance strategies, to charac-
terise the group of children that would otherwise be
missed by existing laboratory surveillance.
Methods
Setting
The Western Cape Province reported the third highest TB
incidence rate (681 per 100,000 population) of the nine
provinces in South Africa in 2015 [14]. During 2013,
34,880 newly diagnosed patients including 5,919 (17.0%)
children < 15 years of age, with DS-TB were reported in
routine provincial TB surveillance data [15]. Prevalence of
HIV co-infection increased with age, from 5% amongst
children < 5 years of age and reaching a high of 46%
amongst adults ≥25 years [15].
TBH is a tertiary referral hospital in the Western Cape
Province and serves approximately 50% of the paediatric
population in the province. TBH has 10 paediatric wards
with 268 general and neonatal beds, and had 15,133 ad-
missions with an overall bed occupancy of 80% during
2012 [16]. TBH serves as referral hospital for uncompli-
cated and complicated TB cases from surrounding high-
burden communities and complicated TB cases from
more remote areas, and provides secondary level paedi-
atric care to children living in adjacent communities.
Children who are medically stable, but require pro-
longed hospitalisation for medical or social reasons, are
referred to dedicated TB hospitals/care facilities.
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6 months with a standard first-line drug regimen, consisting
of isoniazid, rifampicin and pyrazinamide with or without
ethambutol, depending on disease severity [2]. Children
with osteoarticular TB are treated for 9–12 months, while
children with TB meningitis are treated with four drugs
(ethionamide replacing ethambutol) for 6 months if HIV-
uninfected and 9 months if HIV-infected [17]. DR-TB
regimens are individualized for children based on the drug
susceptibility test (DST) results of the child’s M.tb isolate,
or in the case of clinically diagnosed TB, of the adult
source case’s isolate, with treatment ranging from 12 to
24 months.
Study design and population
A prospective cohort study design was used to identify
all children < 13 years of age (based on paediatric admis-
sion criteria at TBH) routinely diagnosed with or treated
for TB at TBH during 2012.
Surveillance strategies
Prospective hospital-based surveillance activities conducted
as part of this study provided the foundation for a health
system strengthening intervention for paediatric TB at
TBH. In addition to active clinical and laboratory surveil-
lance activities, support of TB referral services between
hospital and community-based PHC facilities was provided.
This included TB education to parents/caregivers, support-
ing ward personnel with the referral process, and tele-
phonic follow-up with parents and PHC facilities following
discharge to ensure continuity of care. All health system
strengthening activities were implemented as part of an
integrated package of TB care for children at TBH.
Clinical hospital-based surveillance: a dedicated research
team including a nurse practitioner and lay healthcare
worker, conducted daily clinical surveillance (Monday-Fri-
day) in all 10 medical and surgical paediatric wards to
identify children diagnosed with or treated for TB during
2012. A paper-based childhood TB tracking system (regis-
ter) was implemented in all paediatric wards, outpatient
services and emergency department, to serve as a commu-
nication tool between clinical and research personnel. De-
tailed information regarding clinical surveillance was
communicated to all clinical service personnel at the start
of the study, and regular feedback and training was given at
paediatric departmental meetings.
Laboratory hospital-based surveillance: a dedicated
laboratory-based surveillance officer identified all speci-
mens culture-positive for M. tb at the microbiology la-
boratory at TBH. Laboratory protocols for TB culture
during this time period have been described previously
[10]. This study was implemented prior to the rollout of
Xpert MTB/RIF (Cepheid, Sunnydale, CA) for children in
this setting. Information on culture-positive specimens wascommunicated weekly by the laboratory to the clinical
team.
Data collection
Clinical information was captured on standard case re-
port forms following review of clinical patient records
and laboratory data. Children re-admitted during the
study period were only included once. Information on
TB treatment outcomes was obtained through probabil-
istic record linkage [18] with the 2 provincial electronic
TB registers (2011–2013) using 4 variables (name, sur-
name, gender and date of birth). All matches were manu-
ally reviewed before inclusion. If outcome information
was not found in the TB registers, additional information
was obtained from repeated reviews of medical records
and telephonic contact with the healthcare facilities where
children were discharged to (TB hospitals and PHC facil-
ities). The National Health Laboratory Service database
was also systematically surveyed for follow-up TB micro-
biological investigations in study participants with a
culture-confirmed diagnosis. Data were dual captured in
an access-controlled database and de-identified as soon as
record linkages were completed.
Definitions
Hospital visits resulting in overnight admission were
classified as in-patient visits. Care pathways included
both TB diagnosis pathways in relation to presentation
to TBH as well as referral pathways to continue TB care
on hospital discharge.
The spectrum of TB disease was classified as follows:
pulmonary TB (PTB) only, EPTB only, or both PTB and
EPTB. Intra-thoracic lymphadenopathy was classified as
PTB. Large/loculated pleural effusions and/or miliary TB
were classified as both PTB and EPTB.
We applied standard TB treatment outcome definitions
as per NTP guidelines [2]: Cured: Children who were spu-
tum smear-positive for acid-fast bacilli pre-treatment and
who were sputum smear-negative in the last month of
treatment and on at least one previous occasion, at least
30 days apart. For study purposes, we also included chil-
dren with a positive culture for M. tb (even if smear-
negative), and who had at least one follow-up negative
culture before the end of treatment. Completed treatment:
Children who had completed treatment, but did not meet
the criteria for either cure or treatment failure. This cat-
egory included children with bacteriological confirmation
at diagnosis, but no documented follow-up bacteriological
sample. Children who had documentation of having re-
ceived their last month of treatment in hospital were also
included, even if no further follow-up was documented.
Lost to follow-up: Children whose treatment was inter-
rupted for at least 2 consecutive months. For study pur-
poses, all children who did not have follow-up information
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ment in hospital, or where no formal outcome was
assigned, were also classified as lost to follow-up. Died:
Children who died for any reason during the course of TB
treatment. For study purposes we also included in-hospital
deaths prior to initiation of treatment (e.g. if TB was
culture-confirmed only after the child died). Treatment fail-
ure: Children who remained bacteriologically positive at
5 months or later after starting treatment. Transferred out:
Children who were transferred to another district and for
whom the treatment outcome was not known. Favourable
treatment outcomes were combined as cured or treatment
completed. Unfavourable treatment outcomes included lost
to follow-up (including not evaluated), died, treatment fail-
ure, and transferred out.Statistical analysis
Given the long-standing history of hospital-based labora-
tory surveillance at TBH, the primary aim was to charac-
terise the cohort of children with a clinical/presumed
diagnosis of TB, who would not be identified by existing
microbiological laboratory surveillance. Children were
therefore grouped into those identified through labora-
tory surveillance and those identified through clinical
surveillance only, acknowledging that a proportion of
children identified through laboratory surveillance would
have also been identified through clinical surveillance.
Descriptive and summary statistics were used to calcu-
late numbers and percentages of the overall disease bur-
den, spectrum, clinical characteristics, referral pathways
and TB treatment outcomes. The following variables were
included in analysis: demographics (age and sex), TB treat-
ment and exposure history, HIV status and related vari-
ables, nutritional status, spectrum and type of TB disease,
referral care pathways, and TB treatment outcomes. Odds
ratios (ORs) and 95% confidence intervals (CIs) were cal-
culated in univariate analysis to investigate and quantify
differences between children identified through the two
hospital-based surveillance strategies explained above (la-
boratory vs clinical only). Weights were transformed to z-
scores using reference data available from the 1990 British
Growth Reference [19]. Statistical analysis was completed
using STATA SE version 14 software (StataCorp LP, Texas,
USA).Ethical considerations
Ethics approval was obtained from Stellenbosch Uni-
versity Health Research Ethics Committee (N11/09/
28) and provincial and municipal authorities. As the
study was implemented as part of standard clinical care,
a waiver of individual informed consent was granted. The
STROBE guidelines for reporting of cohort studies were
followed [20].Results
During 2012, 395 children (< 13 years of age) were man-
aged for TB at TBH. Figure 1 provides an overview of
the yield of clinical and laboratory hospital-based sur-
veillance strategies. Although the majority of children
(349, 88.4%) were identified through clinical surveillance,
laboratory-based surveillance identified 158 (40.0%) chil-
dren with culture-confirmed TB. Laboratory surveillance
identified 46 (11.6%) children who were not detected by
clinical ward-based surveillance. Clinical surveillance
identified 237 (60%) of children that would have been
missed by existing laboratory hospital-based surveillance.
Demographic and clinical characteristics for all chil-
dren are presented in Table 1. The median age was
2.4 years (interquartile range [IQR] 1.0–5.1) with 180
(45.6%) children less than 2 years of age; 213 (53.9%)
were male. Hospital admission was required for 361
(91.4%) children, of whom 238 (65.9%) was admitted for
> 1 week. Twenty-six (7%) children had a history of pre-
vious TB treatment. A history of TB exposure was re-
ported in 213 (55.5%), of which 143 (73.3%) occurred in
the household. HIV status was documented in 370
(93.7%), with 90/370 (24.3%) HIV-infected and 24/90
(26.7%) diagnosed with HIV during hospital admission.
Of the 66 children known to be HIV-infected at the time
of admission, 44 (66.7%) were already on antiretroviral
therapy (ART). By 2 weeks following TBH discharge, 83
(92.2%) were receiving ART. Of all TB cases, 113
(29.5%) children had a weight-for-age Z-score < − 3. PTB
only was diagnosed in 207/395 (52.4%), both PTB and
EPTB in 117 (29.6%) and the remaining 71 (18.0%) chil-
dren had only EPTB. TB meningitis and miliary TB were
diagnosed in 62 (15.7%) and 24 (6.1%) children, respect-
ively; 9 children had both. Of 393 children started on
treatment, 342 (87.0%) were treated for DS-TB, 9 (2.3%)
for isoniazid mono-resistant TB, 4 (1.0%) for rifampicin
mono-resistant TB, 34 (8.7%) for multidrug-resistant TB,
3 (0.8%) for pre-extensively drug-resistant TB and 1
(0.2%) for extensively drug-resistant TB. Nine (2.3%) chil-
dren died during hospital admission; 2 with culture-
confirmed DS-TB (results available only after death) died
before TB treatment was initiated.
Ninety-one (23.0%) children had been diagnosed with
TB prior to admission at TBH (Table 2); of these, 76
(83.5%) were diagnosed with TB at hospital level and 41
(45.1%) were diagnosed less than 2 weeks before admis-
sion to TBH. At the time of discharge (n = 386 children),
multiple referral pathways to continue TB care were
followed: 244 (63.2%) were discharged to community-
based PHC facilities, 82 (21.2%) were transferred to dedi-
cated TB hospitals, 28 (7.3%) were discharged home with
monthly outpatient follow-up visits at TBH, 23 (6.0%)
were down-referred to secondary hospitals, 8 (2.1%) were
referred to medium-term care facilities and 1 (0.3%) child
Fig. 1 Overview of the yield of complementary hospital-based surveillance strategies to identify children with tuberculosis.
1Of the 46 children identified only through laboratory surveillance, 27 children were started on TB treatment prior to TBH discharge but missed by
clinical hospital surveillance; 19 were only started on TB treatment at a follow-up visit
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sion at TBH.
Final TB treatment outcomes overall were excellent,
with favourable treatment outcomes in 300/344 (87.2%)
children treated for DS-TB, and 50/51 (98%) treated for
DR-TB (Table 2). Despite the overall favourable out-
comes, mortality was substantial amongst children diag-
nosed with DS-TB (17; 4.9%).
Results of the analysis comparing characteristics be-
tween children identified through the two hospital-based
surveillance strategies (laboratory culture-confirmed vs.
clinical diagnosis only), are presented in Table 3. Labora-
tory surveillance was more likely to identify older
children (5–<13 years of age) compared to children
< 2 years of age (OR 1.7; 95% CI 1.0–2.8; p = 0.042), chil-
dren with EPTB (OR 2.3; 95% CI 1.5–3.6; p < 0.001) es-
pecially in the presence of miliary TB (OR 6.3; 95% CI
2.3–17.8; p < 0.001), and children who died during
hospital admission (OR 5.4; 95% CI 1.1–26.9; p = 0.033).
TB/HIV co-infected patients (OR 0.3; 95% CI 0.2–0.5;
p < 0.001) and in-patients (OR 0.4; 95% CI 0.2–0.9;
p = 0.019) were less likely to be detected by laboratory sur-
veillance. No significant differences were observed for sex,
duration of hospital admission, TB history, documentation
of HIV status, weight-for-age Z-score < − 3, presence of
TB meningitis, type of TB treatment, discharge referral
pathways and TB treatment outcomes.
Discussion
In this TB-endemic setting, our study identified a very
large burden of childhood TB managed at referral hos-
pital level, with almost 400 children during a one-year
period at a single hospital. Clinical surveillance identified
237 (60%) children in addition to the existing laboratory
surveillance. Despite the majority of children being
young (74.9% < 5 years of age), the diagnosis was bac-
teriologically (culture) confirmed in 40% of children.Such a high proportion of confirmed diagnoses is probably
the result of appropriate specimen collection (standard of
care is at least 2 respiratory specimens in children < 5 years
of age or other indicated specimens for EPTB) and the
high proportion of severe forms of TB, which is associated
with higher yield by culture [11]. Nearly 20% of children
had disseminated TB (TB meningitis or miliary TB), asso-
ciated with high morbidity and mortality [21–23]. Almost
a quarter of children were already on TB treatment at the
time of admission, and only 63% of children were referred
to community-based PHC facilities on discharge. This re-
flects both the complexity of TB disease in children with
TB managed at referral hospital level, as well as the as-yet
under-appreciated movement of children between differ-
ent levels of healthcare services during the course of their
TB diagnosis and treatment. The high proportion of chil-
dren with drug-resistant TB (12.9%) reflects that TBH is a
provincial centre of expertise for the management of DR-
TB in children with a dedicated paediatric DR-TB out-
patient service and clinical experts.
To our knowledge, this is the first study to characterize
the TB disease burden, spectrum, clinical care pathways
and final TB treatment outcomes of childhood TB (in-
cluding both confirmed and clinically diagnosed cases)
managed within routine health care services at a large re-
ferral hospital in South Africa. This study therefore com-
prehensively captured the true burden and spectrum of
paediatric TB in a large hospital in a high TB burden set-
ting. We also identified important clinical and care path-
way differences between children identified through
existing laboratory surveillance at this hospital and those
with a presumed diagnoses identified through additional
clinical surveillance.
There are some studies reporting on childhood TB at
tertiary/referral hospitals in Africa. An Ethiopian study re-
ported 491 children treated from 2009 to 2014, and also
found a high proportion (49.4%) of EPTB [24]. However,
Table 1 Demographic and clinical characteristics of children
with tuberculosis managed at Tygerberg Hospital during 2012
Number (%)a
n = 395
Demographics and characteristics at hospital admission
Age (years)
0 - < 2 180 (45.6)
2 - < 5 116 (29.4)
5 – < 13 99 (25.1)
Male sex 213 (53.9)
In-patient admissions 361 (91.4)
Duration of hospitalisation for in-patients (n = 361)
≤ 1 week 123 (34.1)
2–3 weeks 168 (46.5)
≥ 4 weeks 70 (19.4)
TB history
Previous TB treatment reported 26/371 (7.0)
Any TB exposure reported 213/384 (55.5)
Household TB exposure reported
(level of TB exposure documented; n = 195)
143/195 (73.3)
HIV and nutritional status
HIV status documented 370 (93.7)
HIV-infected 90/370 (24.3)
Diagnosed with HIV before hospital
admission
66/90 (73.3)
On ART at hospital admission 44/66 (66.7)
Median CD4 percentageb (inter-quartile range) 17.0 (11.6–23.0)
Median CD4 absolute valueb (inter-quartile range) 593 (274–1,150)
On ART within 2 weeks after hospital
discharge
83/90 (92.2)
Weight-for-Age Z-score < −3c 113/383 (29.5)
TB disease characteristics
Bacteriologically confirmed TB
(culture-positive for M. tb)
158 (40.0)
Spectrum of disease
Pulmonary TB (PTB) only 207 (52.4)
Both PTB and extra-pulmonary TB
(EPTB)
117 (29.6)
EPTB only 71 (18.0)
Disseminated TB (TB Meningitis and Miliary TB) 77 (19.5)
Spectrum of EPTB
TB Meningitisd 62 (15.7)
Miliary TBd 24 (6.1)
TB pleural effusion/empyemae 35 (8.9)
Abdominal TB only 16 (4.1)
Central Nervous System TB (not TB meningitis) 8 (2.0)
Musculoskeletal TB 19 (4.8)
Pericardial effusion 3 (0.8)
Table 1 Demographic and clinical characteristics of children
with tuberculosis managed at Tygerberg Hospital during 2012
(Continued)
Number (%)a
n = 395
Cutaneous TB 1 (0.3)
Renal TB 1 (0.3)
Peripheral lymphadenitis 28 (7.1)
Type of TB treatmentf
First-line regimen (drug-susceptible TB) f 342/393 (87.0)
INH mono-resistant treatment regimen 9/393 (2.3)
Rif mono-resistant treatment regimen 4/393 (1.0)
MDR treatment regimen 34/393 (8.7)
Pre-XDR treatment regimen 3/393 (0.8)
XDR treatment regimen 1/393 (0.2)
Deaths during hospital admission 9 (2.3)
aThe denominator was 395, unless otherwise specified due to missing data
bMedian value of available CD4 laboratory result within 2 weeks before and
after hospital admission (not available for 32/90 HIV-infected children)
cWeights were transformed to z-scores using the reference data available from
the 1990 British Growth Reference
dIncludes 9 children that had both miliary TB and TB meningitis
eTB pleural effusion/empyema includes 4 children with abdominal TB as well
fExcludes two children who died in hospital before any treatment was started,
but subsequently had a drug-susceptible mycobacterial culture
TB Tuberculosis, HIV Human immune-deficiency virus, ART Antiretroviral treat-
ment, M. tb =Mycobacterium tuberculosis, INH Isoniazid, Rif Rifampicin, MDR
Multidrug-resistant, XDR Extensively drug-resistant
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107 (21.8%) children < 5 years of age. In the Ethiopian
study, 82 (28%) children were HIV-infected, but the HIV
status was unknown in a large proportion (41%) [24]. An-
other study from Kinshasa, Democratic Republic of Congo,
reported similar proportions of children with EPTB (159/
283; 56.1%) and 32/97 (33%) were culture-positive for M. tb
during 2005–2011 [25]. However, cultures were only per-
formed on a third of children, and similar to the Ethiopian
study, the age distribution of children was older with only
87 (30.7%) less than 7 years of age. In this study only 2.5%
of children were HIV-infected, but in 75% the status was
not known [25]. The burden of childhood TB reported at
these hospitals was considerably lower than what we have
observed in our study (491/5 years; 283/7 years; 395/
1 year).
Younger and HIV-infected children were less likely to
be identified by existing laboratory surveillance, i.e. they
were less likely to have culture-confirmed TB. This may
reflect clinicians’ lower threshold to diagnose TB in chil-
dren at high risk of developing more severe forms of TB.
Older children, and those with EPTB and disseminated
disease were more likely to be bacteriologically con-
firmed, possibly reflecting a higher likelihood to develop
adult-type pulmonary disease, with a higher bacillary
burden and the ability to produce and expectorate
sputum [3]. Laboratory surveillance also identified a
Table 2 Care pathways and treatment outcomesa of children with tuberculosis managed at Tygerberg Hospital during 2012
TB diagnosis pathways in relation to Tygerberg Hospital (TBH) presentation n = 395 (%)
TB diagnosis made during/following current presentation to TBH 304 (77.0)
TB diagnosis made prior to TBH admission 91 (23.0)
Duration of TB treatment at time of TBH admission (n = 91)
0–14 days on TB treatment 41 (45.1)
15–60 days on TB treatment 23 (25.3)
> 60 days on TB treatment 27 (29.7)
Level of care at which TB diagnosis
was made (n = 91)
Diagnosed at hospital level 76 (83.5)
Diagnosed at a community primary
health care (PHC) facility
15 (16.5)
Discharge referral pathways to continue TB careb
Community-based TB services (PHC facilities) 244/386 (63.2)
Hospital-based outpatient follow–up at TBH 28/386 (7.3)
TB hospitals 82/386 (21.2)
Otherc 32/386 (8.3)
TB treatment outcomes for children treated as drug-susceptible TBd n = 344 (%)
Favourable treatment outcomes (Total) 300 (87.2)
Cured 12 (3.5)
Treatment completed 288 (83.7)
Unfavourable treatment outcomes (Total) 44 (12.8)
Diedd 17 (4.9)
Lost to-follow upe 23 (6.7)
Treatment failure 1 (0.3)
Transferred out 3 (0.9)
TB treatment outcomes for children treated as drug-resistant TBf n = 51 (%)
Favourable treatment outcomes (Total) 50 (98.0)
Cured 14 (27.5)
Treatment completed 36 (70.6)
Unfavourable treatment outcomes (Total) 1 (2.0)
Died 0
Lost to-follow up 1 (2.0)
Treatment failure 0
Transferred out 0
aOutcome information was firstly collected through probabilistic record linkage with electronic TB treatment registers. If information was not found in the
registers, additional follow up information on outcomes were obtained from repeated reviews of medical records, telephonic contact with the facilities patients
were discharged to (TB hospitals and community PHC facilities), as well as the National Health Laboratory Service database
bExcludes children who died during hospital admission (n = 9)
cIncludes referrals to secondary hospitals (n = 23), chronic medium term care facilities (n = 8) and one child that completed TB treatment during a non-TB
related admission
dIncludes two children that died during hospital admission before TB treatment was initiated, but subsequently had a positive culture for drug-susceptible TB
eIncludes 10 children (2.9%) for whom no follow up documentation could be found in any available data sources
fIncludes 9 children with isoniazid mono-resistant TB, 4 with rifampicin mono-resistant TB, 34 with multidrug-resistant TB, and 4 with extensively drug-resistant TB
TB Tuberculosis, TBH Tygerberg Hospital, PHC Primary healthcare
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logical specimens are more readily obtained (e.g. periph-
eral lymphadenitis). However, laboratory surveillance in
isolation is likely to still miss certain types of EPTB, espe-
cially TB meningitis (extremely paucibacillary in theabsence of additional PTB), TB in HIV co-infected chil-
dren and in very young children.
Multiple studies have shown that adult and paediatric
TB patients are at risk of loss to follow-up when moving
between different levels of health care, especially if they
Table 3 Comparing clinical characteristics, referral pathways and TB treatment outcomes of children by two complementary
hospital-based surveillance strategies
All identified through laboratory
surveillance n = 158 (40.0%)a
Identified through clinical surveillance
only n = 237 (60.0%)a
Odds Ratio (95% CI) p-value
Demographics and admission characteristics
Age (years)
0 - < 2 63 (39.9) 117 (49.4) Reference
2 – < 5 48 (30.4) 68 (28.7) 1.3 (0.8–2.1) 0.269
5 – < 13 47 (29.8) 52 (21.9) 1.7 (1.0–2.8) 0.042
Male sex 77 (48.7) 136 (57.4) 0.7 (0.5–1.1) 0.092
In-patient admissions 138 (87.3) 223 (94.1) 0.4 (0.2–0.9) 0.019
Duration of hospitalisation
≤ 1 week 46 (33.3) 77 (34.5) Reference –
2–3 weeks 68 (49.3) 100 (44.8) 1.1 (0.7–1.8) 0.595
≥ 4 weeks 24 (17.4) 46 (20.6) 0.9 (0.5–1.6) 0.666
TB History
Previous TB treatment reported 7/150 (4.7) 19/221 (8.6) 0.5 (0.2–1.3) 0.146
Any TB exposure reported 77/154 (50.0) 136/230 (59.1) 0.7 (0.5–1.0) 0.078
Household TB exposure reported 50/69 (72.5) 93/126 (73.8) 0.9 (0.5–1.8) 0.781
HIV and nutritional status
HIV status documented 146 (92.4) 224 (94.5) 0.7 (0.3–1.6) 0.400
HIV-infected (of those tested) 18/146 (12.3) 72/224 (32.1) 0.3 (0.2–0.5) < 0.001
Weight-for-Age Z-score < − 3b 53/153 (34.6) 60/230 (26.1) 1.5 (1.0–2.3) 0.073
TB disease characteristics
Spectrum of TB disease
PTB only 63 (39.9) 144 (60.8) Reference
ETPB with/without PTB 95 (60.1) 93 (39.2) 2.3 (1.5–3.6) < 0.001
Disseminated TB
TB Meningitisc 20 (12.7) 42 (17.7) 0.7 (0.4–1.2) 0.176
Miliary TBc 19 (12.0) 5 (2.1) 6.3 (2.3–17.8) < 0.001
Type of TB treatment
First-line regimen 134/156 (85.9) d 208/237 (87.8) Reference –
Any drug-resistant regimen 22/156 (14.1) d 29/237 (12.2) 1.2 (0.7–2.1) 0.591
Deaths during hospital admission 7 (4.4) 2 (0.8) 5.4 (1.1–26.9) 0.033
Discharge referral pathway for continuation of TB caree
Community-based PHC facilities 93/151 (61.6) 151/235 (64.3) Reference
Hospital-based outpatient follow-up 9/151 (6.0) 19/235 (8.1) 0.8 (0.3–1.8) 0.537
TB hospitals 37/151 (24.5) 45/235 (19.2) 1.3 (0.8–2.2) 0.263
Otherf 12/151 (8.0) 20/235 (8.5) 1.0 (0.5–2.1) 0.946
TB treatment outcomes (DS-TB)
Favourable 119/136 (87.5) 181/208 (87.0) 1.0 (0.5–2.0) 0.896
Unfavourable 17/136 (12.5) 27/208 (13.0) Reference
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Table 3 Comparing clinical characteristics, referral pathways and TB treatment outcomes of children by two complementary
hospital-based surveillance strategies (Continued)
All identified through laboratory
surveillance n = 158 (40.0%)a
Identified through clinical surveillance
only n = 237 (60.0%)a
Odds Ratio (95% CI) p-value
TB treatment outcomes (DR-TB)
Favourable 22/22 (100) 28/29 (96.6) – 1.000
Unfavourable 0/22 (0.0) 1/29 (3.5)
aThe denominator was 158 or 237 respectively, unless otherwise specified due to missing data
bWeights were transformed to z-scores using the LMS method and the reference data available from 1990 British Growth Reference.; missing admission weights (n = 10)
cInlcudes 9 children that had both miliary TB and TB meningitis
dExcludes two children that died during hospital admission before TB treatment was initiated, but subsequently had a positive culture for drug-susceptible TB
eExcludes children who died in-hospital (n = 9)
fIncludes referrals to secondary hospitals (n= 23), chronic medium term care facilities (n = 8) and one child that completed TB treatment during a non-TB related admission
TB Tuberculosis, CI Confidence interval, HIV Human immune-deficiency virus, ART Antiretroviral treatment, PHC Primary healthcare, DS Drug-susceptible,
DR Drug-resistant
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considerable movement of children between community
PHC facilities, general hospitals and TB hospitals during
their TB episode, possibly increasing the risk of un-
favourable outcomes and incomplete NTP surveillance
data. Almost half of the children received in-patient ter-
tiary care for 2–3 weeks, and a fifth of the children were
referred to TB hospitals for specialized care after dis-
charge. Only approximately two-thirds were referred for
community TB care. An additional advantage of hospital-
based surveillance for paediatric TB, is to provide infor-
mation on hospital admissions and to inform resource
allocation to improve management of children with TB.
Despite the relative resource intensity of clinical surveil-
lance in a large hospital, a major advantage is the ability to
complete linkage to care and real-time follow-up, which is
not feasible when using laboratory-based surveillance only
due to long turn-around time in culture results. This will
be only partially addressed by the shorter turn-around
time of new microbiological methods such as Xpert MTB/
RIF, as current molecular diagnostic methods are less sen-
sitive than culture in paucibacillary TB [28].
Overall TB treatment outcomes were very good des-
pite the young age and the high proportion of children
with severe TB and co-morbidities (HIV co-infection
and malnutrition), especially in children with DR-TB.
The higher proportion of favourable outcomes amongst
children with DR-TB is likely partly a function of the
established high-quality clinical program for the man-
agement of children with DR-TB in this setting and the
more complete follow-up data available in this group of
children. The treatment outcomes observed in the drug-
resistant group are similar to those described previously in
this setting (92% favourable treatment outcomes; n = 149)
[29]. We report favourable outcomes similar to those
observed in a study evaluating routine community-based
surveillance data for children treated for DS-TB in this
setting (85.9%), where children typically would havelimited/uncomplicated disease [30]. However, mortality
among children with DS-TB (4.9%) was considerably
higher than reported from routine community-based NTP
surveillance data (0.7%) from the same setting. Laboratory
hospital-based surveillance identified the majority of
children who died from TB during hospitalization (two
never started TB treatment), and can potentially provide
important information on paediatric mortality. This high-
lights the importance of hospital-based surveillance strat-
egies to better capture TB mortality in children. However,
TB treatment outcome data do not provide information
on morbidity, hospital admission requirements, healthcare
costs and the lifelong disabilities suffered by children and
families resulting from severe forms of TB like TB menin-
gitis, osteoarticular disease (especially spinal TB), and
chronic lung disease from PTB. A long-term outcome
study evaluating children with TB meningitis found that
only 1 in 5 children functioned normally at long-term
follow-up (median follow-up time after completion of
anti-tuberculosis therapy: 6 years 6 months), with 80% suf-
fering cognitive impairment, highlighting the extreme
morbidity and life-long implications of TB meningitis
[31]. Hospital-based surveillance data can therefore pro-
vide important information to the NTP to guide appropri-
ate planning and resource allocation.
Our study had several limitations. All children diag-
nosed with or managed for TB by routine healthcare
services clinicians were included. Over-diagnosis in the
clinically diagnosed group was therefore possible, espe-
cially among very young and HIV-infected children.
However, given the high proportion of children with a
confirmed diagnosis in this cohort, and the specialised
nature of clinical services at the tertiary referral hospital,
we expect the proportion of children who did not truly
have TB to be low. Operational implementation of on-
going clinical surveillance in a hospital with 10 paediat-
ric wards, several outpatients and an emergency unit,
staffed with more than a 100 clinicians was challenging.
du Preez et al. BMC Public Health  (2018) 18:397 Page 10 of 11Study personnel had to rely on hospital clinicians to rec-
ord all children diagnosed over weekends and evaluated
as out-patients in paper-based registers, and clinical sur-
veillance may have missed some patients. The docu-
mented burden of disease in our study would therefore
represent the minimum burden of paediatric TB man-
aged at TBH.
Conclusion
Complementary hospital-based surveillance strategies are
essential to provide a comprehensive picture of the bur-
den, spectrum, referral pathways and outcomes of chil-
dren with TB managed at referral hospital level. It is
important to understand setting-specific and epidemio-
logical differences when interpreting NTP TB data from
different sources of surveillance. Integration of electronic
patient management systems, including hospital data,
could simplify and improve the accuracy of TB reporting
in future. In settings where hospitals do not function as
TB reporting units, the inclusion of hospital surveillance
data within NTP surveillance data should be prioritised.
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